AR047776A1 - Composiciones farmaceuticas glp - 1 - Google Patents

Composiciones farmaceuticas glp - 1

Info

Publication number
AR047776A1
AR047776A1 ARP040104697A ARP040104697A AR047776A1 AR 047776 A1 AR047776 A1 AR 047776A1 AR P040104697 A ARP040104697 A AR P040104697A AR P040104697 A ARP040104697 A AR P040104697A AR 047776 A1 AR047776 A1 AR 047776A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
analogs
peptide
glp
glucagon
Prior art date
Application number
ARP040104697A
Other languages
English (en)
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR047776A1 publication Critical patent/AR047776A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Análogos peptídicos del péptido-1 similar al glucagon, sus sales aceptables desde el punto de vista farmacéutico, a métodos para usar dichos análogos para tratar mamíferos y a composiciones farmacéuticas utiles para este fin que comprenden dichos análogos. Reivindicacion 1: Una composicion farmacéutica que comprende por lo menos una molécula del péptido-1 similar al glucagon, de exendina-4, y de sus análogos y derivados, cuya solubilidad en agua es inferior a 1 mg/ml, con preferencia inferior a 0,5 mg/ml, a un pH entre 6 y 8 y a aproximadamente 4-40sC.
ARP040104697A 2003-12-16 2004-12-16 Composiciones farmaceuticas glp - 1 AR047776A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52993203P 2003-12-16 2003-12-16

Publications (1)

Publication Number Publication Date
AR047776A1 true AR047776A1 (es) 2006-02-22

Family

ID=34700069

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104697A AR047776A1 (es) 2003-12-16 2004-12-16 Composiciones farmaceuticas glp - 1

Country Status (7)

Country Link
US (1) US7521527B2 (es)
EP (1) EP1694278A4 (es)
JP (2) JP2007514752A (es)
AR (1) AR047776A1 (es)
CA (1) CA2550695A1 (es)
TW (1) TWI353250B (es)
WO (1) WO2005058252A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476589C (en) * 2002-02-27 2014-02-25 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US8236759B2 (en) * 2005-06-30 2012-08-07 Ipsen Pharma Sas GLP-1 pharmaceutical compositions
CA2619426C (en) 2005-08-19 2016-06-21 Amylin Pharmaceuticals, Inc. Exendin for treating diabetes and reducing body weight
CA2633070C (en) 2005-12-19 2016-03-08 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
JP2010523473A (ja) * 2006-12-29 2010-07-15 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Ｇｌｐ−１医薬組成物
GEP20125659B (en) * 2006-12-29 2012-10-10 Ipsen Pharma Sas Pharmaceutical compositions containing glucagon-like peptide-1 (glp-1)
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2650006A1 (en) * 2007-09-07 2013-10-16 Ipsen Pharma S.A.S. Analogues of exendin-4 and exendin-3
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009139855A2 (en) * 2008-05-14 2009-11-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of somatostatin-dopamine conjugates
ES2552646T3 (es) 2008-05-21 2015-12-01 Amylin Pharmaceuticals, Inc. Exendinas para disminuir el colesterol y los triglicéridos
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
CN102665401A (zh) 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物
WO2011115871A1 (en) * 2010-03-15 2011-09-22 Ipsen Pharma S.A.S. Pharmaceutical compositions of growth hormone secretagogue receptor ligands
EP2384733B1 (de) 2010-05-07 2016-07-27 Ivoclar Vivadent AG Antimikrobielle Dentalwerkstoffe
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
JP2016503402A (ja) 2012-11-01 2016-02-04 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． ソマトスタチン類似体及びそのダイマー
SG11202000940XA (en) 2017-08-24 2020-02-27 Novo Nordisk As Glp-1 compositions and uses thereof
CA3165359A1 (en) 2020-02-18 2021-07-22 Dorthe Kot Engelund Glp-1 compositions and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3750402T3 (de) 1986-05-05 1997-04-10 Gen Hospital Corp Insulinotropes hormon.
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ES2113879T3 (es) * 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US20010006943A1 (en) * 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
WO1997029180A1 (en) 1996-02-06 1997-08-14 Eli Lilly And Company Diabetes therapy
US6264970B1 (en) * 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
DE19629640C1 (de) 1996-07-23 1997-08-28 Metallgesellschaft Ag Verfahren zur Herstellung von kristallinem D-Sorbit
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
RU2214419C2 (ru) 1996-08-30 2003-10-20 Ново Нордиск А/С Glp-1 производные
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP2002510193A (ja) 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
CN1301172A (zh) * 1998-03-20 2001-06-27 武田药品工业株式会社 生理活性多肽的缓释制剂及其生产
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2205188C2 (ru) * 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
PL202367B1 (pl) * 1998-12-07 2009-06-30 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków
RU2208015C2 (ru) * 1998-12-07 2003-07-10 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас Аналоги гпп-1
WO2000041546A2 (en) * 1999-01-14 2000-07-20 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
CA2369839A1 (en) 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001228327A1 (en) 2000-01-31 2001-08-14 Novo-Nordisk A/S Crystallisation of a glp-1 analogue
ATE424413T1 (de) * 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
AU2002308706A1 (en) * 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
ATE382057T1 (de) * 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
WO2003033671A2 (en) * 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2003035099A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin

Also Published As

Publication number Publication date
TW200520770A (en) 2005-07-01
TWI353250B (en) 2011-12-01
CA2550695A1 (en) 2005-06-30
JP2007514752A (ja) 2007-06-07
EP1694278A4 (en) 2009-08-12
WO2005058252A2 (en) 2005-06-30
JP2011001381A (ja) 2011-01-06
EP1694278A2 (en) 2006-08-30
WO2005058252A3 (en) 2006-08-31
US7521527B2 (en) 2009-04-21
US20050159356A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
AR047776A1 (es) Composiciones farmaceuticas glp - 1
CR7938A (es) Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico
HRP20191614T1 (hr) Spojevi koji su suagonisti gip i glp-1
AR078973A1 (es) Composicion farmaceutica que comprende un agonista de glp-1 y metionina
PE20191143A1 (es) Nuevos compuestos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip
CO5640076A2 (es) Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento
ECSP066653A (es) Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad
BR9915961A (pt) Análogos de glp-1
ECSP20070185A (es) Análogos novedosos de glp-1
AR034132A1 (es) Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica
CO5700705A2 (es) Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad
AR045173A1 (es) Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio
PE20200678A1 (es) Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2)
DE69938669D1 (de) Analoge des glucagon ähnlichen peptides-1 (glp-1)
PE20100447A1 (es) Solucion acuosa inyectable que contiene 4-[[(7r)-8-isopropil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-tetrahidropteridin-2-il]amino]-3-metoxi-n-[(1-ciclopropil-4-piperazinil)fenil]benzamida
CO5550459A2 (es) Inhibidor potente de la serina proteasa del vhc
PE20050130A1 (es) Compuestos organicos
PE20230819A1 (es) Composiciones y usos de glp-1
CR7936A (es) Formulaciones parenterales de un peptido para el tratamiento de lupus sitemico eritematoso
PE20221595A1 (es) Uso terapeutico de un conjugado de accion prolongada de un triple agonista que tiene actividad en todos los receptores de glucagon/glp-1/gip para enfermedades pulmonares
GT199900015A (es) Procedimiento para tratar la insuficiencia cardiaca
NO20080713L (no) Formuleringer for forbedret mucosal levering av PYY
NO20080552L (no) GLP-1 farmasoytiske sammensetninger
WO2004074315A3 (en) Analogues of glp-1
PE20230861A1 (es) Agonistas dobles de glp-1/gip de accion prolongada

Legal Events

Date Code Title Description
FA Abandonment or withdrawal